Science

Robert Brodsky

Feb 27, 2025, 13:40

Robert Brodsky: Haploidentical Bone Marrow Transplantation for Sickle Cell Disease

Robert Brodsky, President of American Society of Hematology and Chief of Hematology at Johns Hopkins, shared an article by Adetola A. Kassim, et al. on X:

“Out in NEJM Evidence today.

KEY TAKEAWAYS:

Of 42 people with severe SCD who had the procedure , 95% were alive at 2 yrs, and 88% are considered cured.
Most people with SCD are eligible, which costs a fraction of the price of gene editing/therapy.

Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.

Authors: Adetola A. Kassim, et al.

Robert Brodsky: Haploidentical Bone Marrow Transplantation for Sickle Cell Disease

Adetola A. Kassim American Society of Hematology ASH Bone Marrow Transplantation cancer fight against cancer Global fight against cancer Johns Hopkins NEJM OncoDaily Oncology Robert Brodsky sickle cell disease

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers